55745-97-6

Basic information

• Product Name: CHROMAN-6-CARBALDEHYDE
• Synonyms: CHROMAN-6-CARBALDEHYDE;Chroman-6-carboxaldehyde;3,4-Dihydro-2H-chromene-6-carboxaldehyde;6-Chromanecarbaldehyde
• CAS NO: 55745-97-6
• Molecular Formula: C₁₀H₁₀O₂
• Molecular Weight: 162.19
• Mol File: 55745-97-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 160-163 °C(Press: 20 Torr)
• Appearance: /
• Density: 1.167±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: CHROMAN-6-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: CHROMAN-6-CARBALDEHYDE(55745-97-6)
• EPA Substance Registry System: CHROMAN-6-CARBALDEHYDE(55745-97-6)

Safety Data

• Hazard Codes: Xi
• Statements: 52
• HazardClass: IRRITANT
• Hazardous Substances Data: 55745-97-6(Hazardous Substances Data)

Usage

General Description

Chroman-6-carbaldehyde is a chemical compound with the formula C9H8O2. Also referred to as Chroman-6-carboxaldehyde or Coumarin-5-carboxaldehyde, this substance belongs to the group of chromans, which are compounds comprising a benzene fused to a heterocyclic ring. Generally, chromans possess a variety of biological activities and can be found naturally in some plants. Chroman-6-carbaldehyde is a colorless, aromatic substance often used as an intermediate compound in the production of many pharmaceutical and agrochemical compounds. Specific details about its toxicity, hazards, or environmental impacts may vary and should be checked on a case-by-case basis.

Upstream product

• 493-08-3 chromane 
• 74-90-8 hydrogen cyanide 
• 68-12-2 N,N-dimethyl-formamide 
• 67856-45-5 6-iodo-chroman 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 91-64-5 coumarin 
• 14864-24-5 (Z)-2-(3-hydroxyprop-1-en-1-yl)phenol 
• 254-04-6 2H-chromene 
• 119-84-6 C₆H₄(CH₂CH₂C(O)O) 
• 1481-92-1 2-(3-hydroxypropyl)phenol 

Downstream Products

• 101352-19-6 chroman-6-carbaldehyde-(2,4-dinitro-phenylhydrazone) 
• 3722-74-5 3,4-Dihydro-6-methyl-2H-1-benzopyran 
• 1418718-38-3 C₃₁H₃₃FN₂O₄ 
• 1418713-79-7 2-(tert-butoxy)-2-(4-(chroman-6-yl)-1-(4-fluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)acetic acid 
• 1418718-41-8 methyl 4-(chroman-6-yl)-1-(3,4-difluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylate 
• 1418718-44-1 (4-(chroman-6-yl)-1-(3,4-difluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)methanol 
• 1418718-47-4 4-(chroman-6-yl)-1-(3,4-difluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde 
• 1418718-53-2 C₂₉H₂₉F₂N₃O₂Si 
• 1418718-50-9 methyl 2-(4-(chroman-6-yl)-1-(3,4-difluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-hydroxyacetate 
• 1418718-56-5 methyl 2-(tert-butoxy)-2-(4-(chroman-6-yl)-1-(3,4-difluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)acetate 
• 1418713-83-3 (R)-2-(tert-butoxy)-2-(4-(chroman-6-yl)-1-(3,4-difluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)acetic acid 
• 1418713-87-7 (S)-2-(tert-butoxy)-2-(4-(chroman-6-yl)-1-(3,4-difluorobenzyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)acetic acid 
• 1403381-89-4 N-[(2E)-2-(3,4-dihydro-2H-1-benzopyran-6-ylmethylidene)cyclohexylidene]hydroxylamine 
• 1403381-88-3 (2E)-2-(3,4-dihydro-2H-1-benzopyran-6-ylmethylidene)cyclohexan-1-one 

Relevant articles and documents

TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV

Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV).